Key Decisions and Approvals
The Board of Directors approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2026, as recommended by the Audit Committee. The meeting commenced at 04:00 p.m. and concluded at 5:00 p.m. on November 13, 2026.
Financial Results Summary (Quarter Ended September 30, 2026)
- Revenue from Operations: ₹1,394.06 lakh (compared to ₹883.67 lakh in Q2 FY26)
- Other Income: ₹23.61 lakh (compared to ₹97.58 lakh in Q2 FY26)
- Total Income: ₹1,417.67 lakh (compared to ₹981.25 lakh in Q2 FY26)
- Total Expenses: ₹1,231.14 lakh (compared to ₹809.27 lakh in Q2 FY26)
- Profit before exceptional items and tax: ₹186.53 lakh (compared to ₹171.98 lakh in Q2 FY26)
- Exceptional items: None
- Tax expense: ₹69.18 lakh (Deferred tax only)
- Profit for the period: ₹117.35 lakh (compared to ₹71.57 lakh in Q2 FY26)
- Basic EPS: ₹1.88 (compared to ₹1.15 in Q2 FY26)
- Diluted EPS: ₹1.88 (compared to ₹1.15 in Q2 FY26)
Half-Yearly Financial Results (Ended September 30, 2026)
- Revenue from Operations: ₹2,270.87 lakh (compared to ₹1,161.09 lakh in H1 FY26)
- Other Income: ₹34.44 lakh (compared to ₹139.23 lakh in H1 FY26)
- Total Income: ₹2,305.31 lakh (compared to ₹1,300.32 lakh in H1 FY26)
- Profit before tax: ₹299.57 lakh (compared to ₹161.44 lakh in H1 FY26)
- Profit for the period: ₹221.90 lakh (compared to ₹61.03 lakh in H1 FY26)
- Basic EPS: ₹3.56 (compared to ₹0.98 in H1 FY26)
- Diluted EPS: ₹3.56 (compared to ₹0.98 in H1 FY26)
Balance Sheet Position (As at September 30, 2026)
- Total Assets: ₹12,685.39 lakh (compared to ₹12,108.35 lakh as at March 31, 2026)
- Property, Plant and Equipment: ₹9,135.73 lakh (compared to ₹7,518.40 lakh)
- Inventories: ₹1,624.16 lakh (compared to ₹1,354.01 lakh)
- Trade Receivables: ₹1,229.03 lakh (compared to ₹915.09 lakh)
- Cash and cash equivalents: ₹99.55 lakh (compared to ₹136.69 lakh)
- Equity Share Capital: ₹623.25 lakh (unchanged)
- Other Equity: ₹4,233.42 lakh (compared to ₹4,011.51 lakh)
- Financial Liabilities (Non-current): ₹4,147.42 lakh (compared to ₹4,331.35 lakh)
- Short-term borrowings: ₹2,153.53 lakh (compared to ₹1,999.17 lakh)
Cash Flow Statement (Half Year Ended September 30, 2026)
- Net cash flow from operating activities: ₹630.65 lakh
- Net cash flow used in investing activities: ₹(361.94) lakh
- Net cash flow used in financing activities: ₹(305.83) lakh
- Net decrease in cash and cash equivalents: ₹(37.13) lakh
Additional Information
- The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34), Companies Act 2013, and SEBI (LODR) Regulations 2015.
- The company operates in a single segment: "Pharmaceuticals".
- The statutory auditors, B. L. Dasharda & Associates, conducted a limited review and issued an unqualified report dated November 13, 2026.
- The results will be published in newspapers in terms of Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015.
- Figures for previous periods have been re-grouped/reworked/re-arranged wherever necessary for comparability.